Scientists shed new light on how early stage breast cancer spreads to other organs

Scientists have shed new light on how early-stage breast cancer spreads to other unidentified organs, which can lead to fatal metastatic cancer in some women years later.

Before a breast cancer tumour is detected, cells that are not yet malignant can spread to other organs where they are dysfunctional and do not replicate, according to new research by Maria Solidad Susa, which is a professor at the Tish Cancer Institute in Mount Sinai. York city

The NR2F1 gene usually prevents pre-malignant cells from spreading to other parts of the body.

Sosa and a team of scientists found that a cancer gene, HER2, suppresses the NR2F1 gene, which causes pre-cancerous cells to move to other parts of the body where they can become cancerous.

“Evidence suggests that even before the primary tumour is detected, you may have cells that have spread to the secondary organs and may eventually metastasize,” Susa said. The lungs, bones and brain are common sites for metastases, or spreads, of breast cancer.

The team was researching. Monday’s review was published Tuesday in the journal Cancer Research. The lab was studied using samples of early-stage breast cancer called ductal carcinoma in situ, or DCIS, as well as cancer lesions in mice.

Susa, the lead author of the study, said that understanding the mechanism by which pre-existing lethal cells spread throughout the body could one day help determine which women are more likely to have recurrent breast cancer. There is danger. If a patient is showing low levels of NR2F1, it may be a sign that inactive cancer cells are spreading in the body where they can later reactivate and cause disease.

The results of the study may affect how DCIS-diagnosed women are treated. DCIS is an abnormal growth of cells in the lining of the mammary gland that has not developed into a malignant tumour. DCIS is traditionally considered non-invasive, meaning that abnormal cells have not yet spread. However, research by Susa’s team and others is challenging this notion.

More than 51,000 women in the United States will be diagnosed with DCIS this year, according to the American Cancer Society. Many women diagnosed with DCIS undergo either surgery or radiation or both. However, women diagnosed with DCIS who undergo these treatments have an approximately 3% chance of dying from breast cancer even after 20 years. According to a basic study published in Comprehensive Oncology in 2015.

More than 150 women in the study who had their breasts removed still died of cancer, meaning the disease had spread by the time it was detected. Scientists have concluded that the classification of DCIS as non-invasive should be reconsidered, warning that some cases of carcinoma have an inherited potential to spread to other parts of the body.

“Whether they have DCIS surgery or are sometimes treated with radiotherapy, the mortality rate does not change. It is telling you that it does not matter what is on your main site. “Susa said. The problem, he said, is that the abnormal cells are spreading from the carcinoma.